These findings offer the proof-of-principle that targeting the IRE1α/XBP-1 pathway may be a therapeutic strategy to decrease the robust inflammatory response of AMs in chronically infected/inflamed CF lungs. Here, ERN1 is linked to cystic fibrosis.